← All trials
NCT04965675
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2021
- Primary completion
- Dec 3, 2023
- Completion date
- Jan 28, 2024
- First posted
- Jul 16, 2021
- Last posted
- Oct 22, 2021
- Enrollment
- 285
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.